Is It Systemic Mastocytosis? Best Practices for Diagnosis and Management

Tracy I. George, MD; Matthew J. Hamilton MD; Anne Maitland, MD, PhD; Lawrence B. Schwartz, MD, PhD

This activity is jointly provided by Global Education Group and Integritas Communications. This activity is endorsed by The Mast Cell Disease Society, Inc.


This educational activity is supported by an educational grant from Blueprint Medicines Corporation.


Tracy I. George, MD (Virtual Professor)
Professor of Pathology
University of Utah School of Medicine
President and Chief Medical Officer
ARUP Laboratories
Salt Lake City, Utah

Matthew J. Hamilton, MD
Assistant Professor of Medicine
Harvard Medical School
Lead Gastroenterologist
Brigham and Women’s Hospital Mastocytosis Center
Boston, Massachusetts

Anne Maitland, MD, PhD
Assistant Clinical Professor, Icahn School of Medicine
Department of Medicine Allergy & Clinical Immunology
New York, New York
Immunologist, Chiari EDS Mast Cell Activation Disorders Center
Mount Sinai South Nassau
Oceanside, New York

Lawrence B. Schwartz, MD, PhD
Charles & Evelyn Thomas Professor of Medicine
Chair, Division of Rheumatology, Allergy & Immunology
Virginia Commonwealth University (VCU)
Richmond, Virginia

Program Description

This Interactive Exchange™ educational program focuses on the identification and management of patients with nonadvanced systemic mastocytosis (SM). The program will open with a brief video segment featuring a 3D animation detailing the pathophysiological drivers of SM and their implications for the development of targeted therapies. Dynamic discussions among a multidisciplinary panel of experts will address challenges in the diagnosis and classification of nonadvanced SM, highlight recent clinical trial data on emerging targeted therapies, and emphasize real-world strategies for the comprehensive management of nonadvanced SM. The program will conclude with an engaging case study discussion highlighting the various clinical presentations of nonadvanced SM along with expert advice for practical and effective disease management.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, dermatologists, gastroenterologists, hematologists/oncologists, and other specialist clinicians who treat patients with nonadvanced systemic mastocytosis.

Learning Objectives

After completing this activity, participants will be better prepared to:

  • Describe clinically relevant pathophysiology in the development of systemic mastocytosis, including the effects of driver mutations on mast cell hyperactivation

  • Identify patients with nonadvanced systemic mastocytosis based on symptomatology and appropriate ancillary testing

  • Discuss the clinical profiles and trial evidence for current and emerging targeted treatment options in nonadvanced systemic mastocytosis

  • Tailor therapeutic regimens for patients with nonadvanced systemic mastocytosis based on symptoms, risk stratification, treatment responses, and appropriate consultations with other specialist clinicians

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.1 hour(s) of pharmacology).

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Tracy I. George, MD - Consulting fees: Blueprint Medicines Corporation, Incyte Corporation, Celgene Corporation, BluPrint Oncology Concepts, UBC (United BioSource LLC), Allakos Inc; Contracted Research: Blueprint Medicines Corporation, Incyte Corporation, Celgene Corporation, Deciphera Pharmaceuticals, Inc., Cogent Biosciences, Inc.; all received by ARUP Laboratories

Matthew J. Hamilton MD - Consulting fees: Allakos Inc., GlaxoSmithKline

Anne Maitland, MD, PhD  - Nothing to disclose.

Lawrence B. Schwartz, MD, PhD - Consulting fees: Allakos Inc., AstraZeneca, Blueprint Medicines Corporation, Celidex, CSL Behring, Genentech, GLG Pharma Corporation, GlaxoSmithKline, Inves, Takeda; Contracted Research: Blueprint Medicines Corporation, Deciphera; Royalty: BioLegent, Genentech, Hycult Biotech, Millipore, Santa Cruz, Thermo Fisher-Phadia

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Gena Dolson, MS: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to received credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.

Term of Offering

This activity was released on April 29, 2022, and is valid for one year. Requests for credit must be made no later than April 29, 2023. 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Education Group Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 1.00

credit type CME/AANP

release 04/29/2022

expiration 04/29/2023

type Webcast